Eisai Co Ltd

Juanmonino | E+ | Getty ImagesSeniors with early Alzheimer's disease will face major hurdles to get treated even if promising new drugs roll out more broadly in the coming years, putting them at risk of developing more severe disease as…

Chiquita Brooks-LaSure testifies before the Senate Finance Committee during her nomination hearing to be administrator of the Centers for Medicare & Medicaid Services in Washington on Thursday, April 15, 2021.Caroline Brehman | CQ-Roll…

A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesBiogen isn't worried about competing with Eli Lilly as they both attempt to bring an Alzheimer's…

Research at BiogenSource: BiogenAlzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows. The Japanese drugmaker and its partner Biogen last week released an…

Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022.Jakub Porzycki | Nurphoto | Getty ImagesEli Lilly's…

The Veterans' Health Administration will cover Eisai and Biogen's Alzheimer's treatment Leqembi for some patients, the companies announced on Monday.In a statement, Eisai said veterans in the early stages of the disease who meet VHA…

Andrew Brookes | Image Source | Getty ImagesThe Food and Drug Administration will make a decision on whether to fully approve Eisai's and Biogen's Alzheimer's treatment Leqembi by July 6, the companies announced on Monday.Leqembi is an…

Medicare will not provide broader coverage of the Alzheimer's drug Leqembi until it receives more evidence that the treatment is reasonable and necessary, according to the federal agency that runs the program for seniors.The Centers for…

U.S. senators on Friday called for Medicare to offer broad coverage of Alzheimer's treatments approved by the Food and Drug Administration, warning that current restrictions cost patients precious time as their disease progresses."Given the…

Tek Image/science Photo Library | Science Photo Library | Getty ImagesJapanese drugmaker Eisai expects the Food and Drug Administration to fully approve its Alzheimer's treatment Leqembi this summer, which would expand access to the pricey…